SLNO · As filed with the SEC
Soleno Therapeutics income statement, by quarter
The statement as Soleno Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited) · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 |
|---|---|---|---|---|---|---|
| Revenue | ||||||
| Product revenue, net | 94,603,000 | — | 66,018,000 | 32,657,000 | — | — |
| Product | — | — | — | 32,657,000 | — | — |
| Operating expenses | ||||||
| Cost of goods sold | 1,198,000 | — | 1,141,000 | 696,000 | — | — |
| Research and development | 11,274,000 | — | 8,405,000 | 9,147,000 | 13,517,000 | — |
| Selling, general and administrative | 50,369,000 | — | 33,753,000 | 28,238,000 | 29,259,000 | — |
| Change in fair value of contingent consideration | 484,000 | — | 614,000 | 1,101,000 | 2,967,000 | — |
| Total operating expenses | — | — | — | — | 45,743,000 | — |
| Total operating expenses | 63,325,000 | — | 43,913,000 | 39,182,000 | — | — |
| Operating income (loss) | 31,278,000 | — | 22,105,000 | (6,525,000) | (45,743,000) | — |
| Other income (expense), net | ||||||
| Interest income, net | 4,927,000 | — | 5,298,000 | 3,193,000 | 3,331,000 | — |
| Interest expense | (1,292,000) | — | (1,390,000) | (1,376,000) | (1,361,000) | — |
| Total other income (expense), net | 3,635,000 | — | 3,908,000 | 1,817,000 | 1,970,000 | — |
| Income (loss) before provision for income taxes | 34,913,000 | — | — | — | — | — |
| Provision for income taxes | 3,535,000 | — | — | — | — | — |
| Net income (loss) | 31,378,000 | — | 26,013,000 | (4,708,000) | (43,773,000) | — |
| Other comprehensive income (loss) | ||||||
| Net unrealized gain (loss) on marketable securities | (2,225,000) | — | 261,000 | (153,000) | (139,000) | — |
| Foreign currency translation adjustment | (28,000) | — | 14,000 | 12,000 | 4,000 | — |
| Total comprehensive income (loss) | 29,125,000 | — | 26,288,000 | (4,849,000) | (43,908,000) | — |
| Less: Undistributed earnings attributable to participating securities, basic | (1,000) | — | — | — | — | — |
| Less: Undistributed earnings attributable to participating securities, diluted | (1,000) | — | — | — | — | — |
| Net income (loss) attributable to common stockholders - basic | 31,377,000 | — | — | — | — | — |
| Net income (loss) attributable to common stockholders - diluted | 31,377,000 | — | — | — | — | — |
| Net income (loss) per share - basic | 0.6 | — | 0.49 | (0.09) | (0.95) | — |
| Net income (loss) per share - diluted | 0.59 | — | 0.47 | (0.09) | (0.95) | — |
| Weighted-average common shares outstanding - basic | 52,091,047 | — | 53,328,094 | 50,483,281 | 46,178,793 | — |
| Weighted-average common shares outstanding - diluted | 53,066,971 | — | 54,921,916 | 50,483,281 | 46,178,793 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.